We are live on
!
Find out more
AQR Capital Management Portfolio holdings
AUM
$218B
1-Year Est. Return
29.41%
This Fund
S&P 500
This Quarter
Est. Return
-12.77%
1 Year Est. Return
+29.41%
3 Year Est. Return
+92.15%
5 Year Est. Return
+116.61%
10 Year Est. Return
+435.72%
AUM
$44.2B
AUM Growth
-$8.44B
(-16%)
Cap. Flow
-$301M
Cap. Flow
% of AUM
-0.68%
Top 10 Holdings %
Top 10 Hldgs %
14.01%
Holding
2,360
New
150
Increased
1,005
Reduced
998
Closed
187
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$209M |
| 2 |
CVS Health
CVS
|
+$195M |
| 3 |
Tyson Foods
TSN
|
+$136M |
| 4 |
ExxonMobil
XOM
|
+$135M |
| 5 |
LyondellBasell Industries
LYB
|
+$130M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Thermo Fisher Scientific
TMO
|
+$239M |
| 2 |
Microsoft
MSFT
|
+$204M |
| 3 |
Johnson & Johnson
JNJ
|
+$157M |
| 4 |
Amazon
AMZN
|
+$144M |
| 5 |
Walmart Inc
WMT
|
+$137M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.23% |
| 2 | Healthcare | 16.49% |
| 3 | Financials | 11.74% |
| 4 | Industrials | 11.47% |
| 5 | Consumer Discretionary | 10.94% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2026
Sabre
SABR
$835M
| $157K | ﹤0.01% |
27,058
-449,633
| -94% | -$3.75M |
|
2027
SI-BONE Inc
SIBN
$844M
| $157K | ﹤0.01% |
+11,928
| New | +$199K |
|
2028
NeoGenomics
NEO
$2.14B
| $156K | ﹤0.01% |
19,140
+7,042
| +58% | +$67.2K |
|
|
TRUE
2029
DELISTED
TrueCar
TRUE
| $156K | ﹤0.01% |
60,410
-200,363
| -77% | -$664K |
|
|
FPI
2030
Farmland Partners
FPI
$424M
| $154K | ﹤0.01% |
11,192
-2,583
| -19% | -$37.6K |
|
|
CMBM
2031
DELISTED
Cambium Networks
CMBM
| $153K | ﹤0.01% |
10,444
-856
| -8% | -$13.5K |
|
2032
Cerus
CERS
$508M
| $151K | ﹤0.01% |
28,490
-17,580
| -38% | -$87.8K |
|
2033
Korro Bio
KRRO
$199M
| $151K | ﹤0.01% |
2,016
+1,432
| +245% | +$96.8K |
|
2034
MannKind Corp
MNKD
$1.26B
| $151K | ﹤0.01% |
39,517
| – | – |
|
2035
Aclaris Therapeutics
ACRS
$867M
| $150K | ﹤0.01% |
10,752
-64
| -0.6% | -$897 |
|
2036
Diamondrock Hospitality Co
DRH
$2.48B
| $148K | ﹤0.01% |
18,061
+1,919
| +12% | +$18.7K |
|
2037
Shattuck Labs
STTK
$682M
| $148K | ﹤0.01% |
36,426
-4,304
| -11% | -$15.6K |
|
|
CTEV
2038
Claritev Corp
CTEV
$581M
| $148K | ﹤0.01% |
+673
| New | +$133K |
|
2039
CuriosityStream
CURI
$166M
| $145K | ﹤0.01% |
+85,911
| New | +$173K |
|
2040
NovaGold Resources
NG
$3.35B
| $144K | ﹤0.01% |
29,837
+15,577
| +109% | +$97.3K |
|
2041
Vroom Inc
VRM
$51.2M
| $144K | ﹤0.01% |
1,517
+1,340
| +757% | +$168K |
|
|
VLDR
2042
DELISTED
Velodyne Lidar, Inc. Common Stock
VLDR
| $143K | ﹤0.01% |
+149,512
| New | +$258K |
|
2043
Liquidity Services
LQDT
$1.28B
| $142K | ﹤0.01% |
10,563
+426
| +4% | +$6.27K |
|
2044
Ocular Therapeutix
OCUL
$2.03B
| $142K | ﹤0.01% |
35,342
+6,947
| +24% | +$26.2K |
|
|
AGNT
2045
AGNT Inc
AGNT
$715M
| $141K | ﹤0.01% |
12,004
-12,459
| -51% | -$180K |
|
2046
Montauk Renewables
MNTK
$243M
| $141K | ﹤0.01% |
+14,071
| New | +$168K |
|
|
LGF.B
2047
DELISTED
Lions Gate Entertainment Corp. Class B Non-Voting Shares
LGF.B
| $141K | ﹤0.01% |
15,976
-14,496
| -48% | -$165K |
|
2048
SIGA Technologies
SIGA
$210M
| $140K | ﹤0.01% |
+12,097
| New | +$109K |
|
|
RUBY
2049
DELISTED
Rubius Therapeutics, Inc
RUBY
| $140K | ﹤0.01% |
+164,161
| New | +$276K |
|
2050
Rithm Capital
RITM
$5.65B
| $138K | ﹤0.01% |
14,799
-26,933
| -65% | -$283K |
|
Similar funds
VGA
AQR Capital Management's Q2 2022 Portfolio in Review
As of Q2 2022, AQR Capital Management held 2,360 positions worth $44.2B, down 16% from $52.7B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
AQR Capital Management's Q2 2022 filing shows 150 new, 1,005 increased, 998 reduced and 187 closed positions. Its largest new stake was Fluor: 339,891 shares worth $7.86M. The largest sale was Thermo Fisher Scientific, an estimated $239M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 23% a quarter earlier, followed by Healthcare and Financials.
- AQR Capital Management's largest Q2 2022 buy was Fluor: 339,891 shares worth $7.86M.
- AQR Capital Management added most to Gilead Sciences in Q2 2022, an estimated $209M increase.
- AQR Capital Management's biggest Q2 2022 reduction was Thermo Fisher Scientific, cutting an estimated $239M.
- AQR Capital Management fully exited Roku in Q2 2022, selling an estimated $32.5M.
- AQR Capital Management's ten largest holdings make up 14% of its $44.2B portfolio in Q2 2022.
- AQR Capital Management opened 150 new positions and closed 187 in Q2 2022.
- AQR Capital Management's portfolio value fell 16% quarter-over-quarter to $44.2B.
Based on AQR Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.